Findings

What do systematic reviews say?

6 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Leuprorelin vs treosulfan

Progression‐free survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

It is very uncertain whether leuprorelin changes progression‐free survival at 6 months№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).

2 findings from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 0.61 [0.22, 1.68]
Studies not reported
Very low
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 0.65 [0.12, 3.66]
Studies not reported
Very low

Leuprorelin vs treosulfan

Overall survival · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

It is very uncertain whether leuprorelin changes overall survival compared with treosulfan (very low certainty).

1 finding from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
HR 0.98 [0.58, 1.67]
Studies not reported
Very low

Leuprorelin vs treosulfan

Skin toxicity (alopecia)№ of participants: 73(1 RCT) · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

It is very uncertain whether leuprorelin changes skin toxicity (alopecia)№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).

1 finding from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 0.32 [0.12, 0.91]
Studies not reported
Very low

Leuprorelin vs treosulfan

Nausea and vomiting · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

It is very uncertain whether leuprorelin changes gastrointestinal toxicity (nausea and vomiting)№ of participants:… compared with treosulfan (very low certainty).

1 finding from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 0.65 [0.12, 3.66]
Studies not reported
Very low

Leuprorelin vs treosulfan

Neurotoxicity · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

It is very uncertain whether leuprorelin changes neurotoxicity№ of participants: 73(1 RCT) compared with treosulfan (very low certainty).

1 finding from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
RR 0.32 [0.01, 7.71]
Studies not reported
Very low

Leuprorelin vs treosulfan

Grade 3 to 4 neutropenia · Platinum‐resistant and refractory (relapsed) epithelial ovarian cancer

1 finding from 1 review

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low